Jasper Therapeutics Receives Nasdaq Notice of Equity Noncompliance

What Happened
Jasper Therapeutics, Inc. (JSPR) filed an 8-K reporting that on August 21, 2026 Nasdaq notified the company it no longer satisfies the $2,500,000 minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1), based on the company’s Form 10-Q for the quarter ended June 30, 2026. The Notice does not have an immediate effect on the company’s listing or trading. The company says it will submit a Compliance Plan and intends to seek stockholder approval to convert outstanding Non‑Voting Convertible Preferred Stock at a special meeting to regain compliance, but offers no assurance of success.

Key Details

• Nasdaq Notice date: August 21, 2026; deficiency based on the Q2 2026 Form 10-Q (period ended June 30, 2026).
• Minimum requirement missed: $2,500,000 in stockholders’ equity (Nasdaq Listing Rule 5550(b)(1)).
• Deadline to submit a Compliance Plan: 45 calendar days from the Notice (until October 5, 2026).
• Possible timeline if plan accepted: up to a 180-calendar-day extension from August 21, 2026 to regain compliance.
• Company action: intends to seek stockholder approval to convert its Non‑Voting Convertible Preferred Stock at a special meeting and will submit a Compliance Plan; may request a hearing before Nasdaq’s Hearing Panel if needed.

Why It Matters
This filing signals a regulatory compliance issue that could, if unresolved, lead to delisting from Nasdaq—affecting liquidity, investor access, and possibly share price. There is no immediate trading impact from the Notice, and the company has procedural options (Compliance Plan, stockholder vote, and a hearing) that can delay or prevent delisting. Retail investors should note the timelines (Oct 5, 2026 for plan filing and up to a 180-day extension) and the company’s reliance on a planned conversion of preferred stock and stockholder approval to restore required equity.